Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01065844 · ClinicalTrials.gov registry record · Phase 2
Nelfinavir in Recurrent Adenoid Cystic Cancer of the Head and Neck
A Phase 2 study, sponsored by University of Iowa.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT01065844 is a Phase 2 study that has completed, run by University of Iowa. The registered enrollment target is 15 participants.
The verdict
NCT01065844, a Phase 2 study, has completed, sponsored by University of Iowa.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the FDA-approved drug nelfinavir (NFV) as an oncologic agent for adenoid cystic cancers of the head and neck. Specifically, subjects will be asked to take 1250 mg twice daily and follow-up with their medical oncologist as clinically indicated while taking this medication. Subjects would be evaluated for quality of life issues utilizing the EORTC QLQ-C30 2-page questionnaire. Subjects would also be evaluated clinically by the oncologist to determine if the NFV was having an anti-neoplastic effect. The study remains unfunded. Therefore, potential subjects must be willing to provide self-travel to study site. This study requires a screening visit, initial study visit, and monthly follow-up. Subjects are not reimbursed for time, travel, or physician costs.
Interventions
- DRUG Nelfinavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2009-10 |
| Est. Completion | 2017-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01065844
The ClinicalTrials.gov registry entry for NCT01065844 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Iowa, which has 228 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nelfinavir is the first listed.
NCT01065844 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01065844 about?
NCT01065844 is a clinical study titled "Nelfinavir in Recurrent Adenoid Cystic Cancer of the Head and Neck". The purpose of this study is to evaluate the FDA-approved drug nelfinavir (NFV) as an oncologic agent for adenoid cystic cancers of the head and neck. Specifically, subjects will be asked to take 1250 mg twice daily and follow-up with their medical oncologist as clinically indicated while taking th...
What is the current status of trial NCT01065844?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2009-10. Estimated completion is 2017-11.
What interventions are being tested in trial NCT01065844?
The interventions under investigation include: Nelfinavir (DRUG).
Who is sponsoring clinical trial NCT01065844?
This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.